News

Novel optogenetics gene therapies for patients with blinding diseases

News

Biotech Startup Ray Raises $100M for Vision-Restoring Gene Therapies

Press Releases

Ray Therapeutics Awarded $8M CIRM Grant to Advance RTx-015 Gene Therapy for Retinitis Pigmentosa

Funding will support ongoing clinical development of optogenetic therapy to restore vision BERKELEY, Calif.–Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for vision…

Ray Therapeutics Appoints Christopher Whitmore as Chief Financial Officer

San Francisco, CA – September 16, 2024 – Ray Therapeutics, a leading optogenetics company, announced today the appointment of Christopher Whitmore as Chief Financial…

Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases

Funds will advance Ray Therapeutics’ optogenetics gene therapy programs for blinding retinal diseases….

Ray Therapeutics to Present at Upcoming Scientific Conferences

We’re delighted to present our data which shows the power of visual optogenetics as a disruptive technology with the potential to restore vision to…
©Ray Therapeutics. All rights reserved | Site by BKW